Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

WHO emphasizes integrating surveillance into national STI programs. Zoliflodacin, a novel antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ...

The terms “gender ideology” and “transgender ideology,” have become ubiquitous — in government documents and policy announcements, in mass media and in online disputes.

Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM ESTCompany ParticipantsPeter Dannenbaum - Vice ...

On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics(NASDAQ:CDTX), increasing its position value by approximately $167.48 ...

Either we get ahead of this crisis or watch a generation of Americans be swept into the devastating grip of disease.

The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

China will finance HIV-prevention programs in South Africa for the first time, taking a small step into the massive void left by US funding cuts earlier this year.

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...